21 results about "Antibiotic therapy" patented technology

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

This application provides a method and system for predicting urinary tract infections related to urodynamic examinations. It addresses the limitations of current preventative measures, where methods with high evidence levels and good efficacy, including antibiotic intravesical instillation and weekly oral cyclic antibiotic therapy, inevitably require antibiotic use. The method includes: acquiring urodynamic examination data from a target patient; analyzing the curve information in the urodynamic examination data to obtain a curve numerical sequence corresponding to a time axis; extracting a urodynamic feature set based on the curve numerical sequence; constructing a medical history feature set based on the target patient's medical history data; inputting the urodynamic feature set and the medical history feature set into a urinary tract infection risk prediction model to output a risk prediction result for urinary tract infection after urodynamic examination. The risk prediction result includes at least a risk score or risk stratification result.

A platform and method for testing antibiotic sensitivity of a polymicrobial infection is provided. The platform includes a body defining a plurality of sets of chambers and a plurality of wells. Each set of chambers has a plurality of chambers adapted for culturing microbes of the polymicrobial infection therein. Each well is associated with a corresponding set of chambers and has an input in fluidic communication with the outlets of the plurality of chambers in the corresponding set of chambers. Selected antibiotic therapies may be received in the wells which fluidically connect the plurality of chambers in a corresponding set of chambers such that microbes cultured in the plurality of chambers in the corresponding set of chambers are in soluble factor contact.

The invention belongs to the technical field of prevention and control of drug-resistant bacteria, and particularly discloses a composite bactericidal composition and application thereof in preparation of a reagent for killing aeromonas hydrophila oxytetracycline drug-resistant strains. The minimum inhibitory concentration of the epsilon-polylysine to an aeromonas hydrophila oxytetracycline drug-resistant strain is as low as 3.125 g / mL. Meanwhile, the sterilization mechanism of the epsilon-polylysine on aeromonas hydrophila oxytetracycline drug-resistant strains is discussed through metabonomics research. On the basis, the application finds that various exogenous small molecule metabolites such as 2-phenylacetamide and the like are combined with epsilon-polylysine for use, so that the absorption of drug-resistant bacteria on epsilon-polylysine can be promoted, the sterilization effect of the epsilon-polylysine is effectively enhanced, and the problem of drug resistance of bacteria is solved. Therefore, when the epsilon-polylysine and the exogenous small molecule metabolite are jointly applied, compared with the existing single antibiotic therapy, the epsilon-polylysine has higher activity and better safety and operability in preparation of the reagent for resisting the aeromonas hydrophila oxytetracycline drug-resistant strain.

A polyester coacervate capable of disrupting biofilms formed on substrates and methods of treating contaminated substrates to disrupt and remove biofilms using polyester coacervates without the need for antibiotic therapies or mechanical disruption. The polyester coacervate exhibits tunable viscosity, hydrophobic / hydrophilic, and interfacial properties to disrupt and remove a broad range of biofilms formed on a broad range of substrates.

The invention discloses a gelled cell as well as a preparation method and application thereof. Relates to the field of synthetic biology and biomedicine. The gelated cell is a cell structure without cell viability, and comprises: a carrier cell framework comprising a cell membrane which retains the membrane protein content, the type and the lipid order of an original carrier cell; the intracellular hydrogel is formed in situ in the carrier cell framework through supramolecular host-guest interaction or cross-linking reaction, and is fused with the inner surface of a cell membrane; the antibacterial substance is loaded in the intracellular hydrogel; wherein pores are distributed on the cell membrane, the intracellular hydrogel is communicated with the external environment through the pores, and the loaded antibacterial substances are exposed. The gelated cell provided by the invention can simultaneously realize targeted delivery, contact sterilization and endotoxin adsorption, and avoids the problem of secondary inflammation caused by release of endotoxin in traditional antibiotic therapy and the problem of membrane protein loss or disordered arrangement in a cell membrane coating technology.

The invention discloses a traditional Chinese medicine composition which has a relatively strong bacteriostatic effect on helicobacter pylori and has a treatment effect on helicobacter pylori infectious gastritis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-52 parts of matricaria recutita, 6-56 parts of clove, 12-74 parts of lithocarpus polystachyus, 13-54 parts of radix angelicae, 6-47 parts of hypericum japonicum, 15-63 parts of scutellaria baicalensis and 15-42 parts of liquorice. The bacteriostasis rate is larger than or equal to 90%, the gastritis treatment principle is equivalent to drinking of traditional Chinese medicine powerful bacteriostasis liquid medicine to inhibit and kill helicobacter pylori in the stomach, and the liquid medicine with bacteriostasis, inflammation diminishing, detumescence and apocenosis is applied to the gastric mucosa. And for the helicobacter pylori infected people with antibiotic resistance or unsuitable for antibiotic therapy, the eradication rate of helicobacter pylori infection can be improved, and the application value in the field of medicine is very high. The invention is used in the fields of health-preserving health-care food and plant beverage, can reduce the infection risk of helicobacter pylori, and has very high social health prevention and control benefit value.

The present invention belongs to the field of feed technology, and discloses a high-iron feed for preventing and treating Clostridium difficile infection in mice and its application. The raw material composition of the high-iron feed is as follows in g / kg: casein 200, L-cystine 3, corn starch 397.5, maltodextrin 132, sucrose 100, cellulose 50, soybean oil 70, mixed vitamins 10, mixed minerals 35, and ferrous sulfate 0.4. The high-iron feed can be used as a dietary intervention for intestinal inflammation caused by Clostridium difficile infection in mice. Through animal experiments, it was found that the high-iron feed can effectively inhibit the colonization and germination of Clostridium difficile spores in mice, alleviate clinical symptoms such as weight loss, diarrhea, and hunchback caused by Clostridium difficile infection, increase the secretion of beneficial compounds such as tauroursodeoxycholic acid and trillium glycosides, reduce the production of inflammatory cells and inflammatory factors, and thus alleviate Clostridium difficile infectious enteritis. It provides important experimental data for the development of non-antibiotic therapy for Clostridium difficile, and has good application prospects and huge potential value.

Provided herein are rapid and effective local infection therapy methods, systems, and devices that significantly reduce the mortality, morbidity, and the cost of care in rare musculoskeletal infections. Continuous delivery of antibiotic therapy locally, at the infection site, reduces edema and provides antibiotic irrigation, significantly improving outcomes while reducing the need for systemic antibiotics.

The invention relates to a novel topical pharmaceutical composition comprising ceftizoxime, a third-generation cephalosporin antibiotic, complexed with sulfobutyl ether-β-cyclodextrin (SBE-β-CD) to enhance solubility and stability in aqueous environments. The sterile, sprayable formulation is intended for direct topical use or dilution for the treatment and prevention of bacterial skin and wound infections. To overcome ceftizoxime's aqueous instability, the invention employs inclusion complexation with 2–10% w / v SBE-β-CD, prepared by shaking at 30°C for 72 hours followed by sterile filtration. Differential Scanning Calorimetry (DSC) confirms molecular encapsulation through suppression of the ceftizoxime melting peak, indicating loss of crystallinity. Antibacterial efficacy is demonstrated against Staphylococcus aureus and Escherichia coli using zone of inhibition assays. UV–Vis spectrophotometry at 258 nm confirms high linearity (R² = 0.998) for quantitative analysis. The formulation offers a stable, scalable, and patient-friendly alternative for localized antibiotic therapy and surgical prophylaxis with reduced systemic exposure.

A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.

The present invention relates to a method for guiding, stratifying, and / or controlling antibiotic therapy in a patient suspected of having an infection. Specifically, the method includes providing a sample from the patient, determining the level of proADM or one or more fragments thereof in the sample, and wherein the level of proADM or one or more fragments thereof in the sample indicates whether antibiotic treatment needs to be initiated or changed. In a preferred embodiment of the present invention, the method further includes determining the level of PCT or one or more fragments thereof in a sample from the patient. In addition, the present invention also relates to a kit for performing the method of the present invention.

The application discloses sulfhydrylated oxidized guar gum / sodium alginate microspheres and a preparation method and application thereof, and belongs to the field of biomedical materials. The sulfhydrylated oxidized guar gum and a sodium alginate base material are used to prepare and construct microspheres with pH response, colon targeting and intestinal adhesion by an emulsion gel method, the microsphere technology is used to embed probiotics, and the survival rate of the probiotics in gastric juice is improved. Through in-vitro verification, the method of embedding the microspheres successfully prevents the direct contact of the probiotics with a harsh environment, improves the ability of the probiotics to resist strong acid in the gastrointestinal tract, and enhances the adhesion and colonization effect of the probiotics in the intestinal tract. Through an animal experiment of simulating colitis, the LGG microspheres have the best treatment effect on colitis. Compared with a large number of side effects caused by antibiotic therapy, the treatment method has a certain clinical application prospect as a means with biological safety to treat inflammatory bowel disease.

A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.

The embodiment of the specification provides a nitrogen nanobubble water composition, a method for inhibiting helicobacter pylori and application, for inhibiting helicobacter pylori, the composition takes nitrogen nanobubble water as an active component, the bubble density of the nitrogen nanobubble water is, the average diameter is 60-100 nm, and the oxidation-reduction potential is 200-250 mV.The composition does not add any chemical antibiotic or antibacterial agent, achieves bacteriostasis through the physical energy and microenvironment regulation of nanobubbles, cannot induce the drug resistance of bacteria, can be used repeatedly for a long time, and fundamentally solves the drug resistance problem faced by traditional antibiotic therapy.The composition can be prepared into mouthwash, oral spray, oral cleaning solution, drinking water, functional beverage, oral cleaning appliance liquid, gastric perfusion liquid and various product forms, covers multiple application scenarios such as daily oral care, gastric health management and clinical medical treatment, and meets different use requirements.

The invention relates to a novel fusion protein, an immunogenic composition, a recombinant vaccine and the like for preventing and treating chlamydia psittaci infection. The fusion protein provided by the invention contains fusion proteins coded by four genes of rplE, rpsC, rpsE and rpsG, and has good immunogenicity. Compared with a traditional antibiotic therapy, the nucleic acid vaccine constructed by the fusion protein can provide an effective immune protection effect, remarkably inhibit chlamydia psittaci infection, effectively eliminate chlamydia psittaci colonization and avoid repeated infection, and has a wide application prospect.

The invention discloses a preparation method and application of clostridium butyricum-sourced extracellular vesicles, the extracellular vesicles (CBEVs) are separated and purified from clostridium butyricum, and through structural characterization, metabonomics and multi-function verification, the extracellular vesicles (CBEVs) have a good application prospect. Results show that the extracellular vesicle has multiple effects of resisting helicobacter pylori activity and gastric mucosa penetrability, inhibiting bacterial adhesion and biofilm formation, reducing gastric mucosa inflammatory factors and the like, and is non-toxic to gastric epithelial cells. Compared with the existing antibiotic and probiotic therapy, the vesicle has a remarkable antibacterial effect on sensitive helicobacter pylori and drug-resistant strains, solves the problems of high drug resistance, large side effect and the like of the existing antibiotic therapy for helicobacter pylori, avoids the problem of viable bacterium colonization failure of probiotics, and is higher in safety and suitable for long-term treatment and prevention. In addition, due to the natural source characteristic, excellent biocompatibility is achieved, and an innovative direction is provided for developing novel antibacterial drugs.

The present application relates to the technical field of biological medicine, in particular to an antibody against staphylococcus aureus enterotoxin B and application thereof. The heavy chain variable region of the antibody provided in the present application comprises CDR sequences as shown in SEQ ID NO. 1-3, and the light chain variable region comprises CDR sequences as shown in SEQ ID NO. 9-11. The antibody has high affinity and can specifically bind to staphylococcus aureus SEB, can block the combination of SEB and MHC II / TCR, significantly inhibit cytokine storm, and exhibit dose-dependent protection effect in the MRSA systemic infection model, and can be used for treating, preventing or diagnosing staphylococcus aureus infection, and provides a non-antibiotic therapy solution for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health value.

The present disclosure relates to a method for predicting the appropriateness of antibiotic use in a patient with an infectious disease and a device thereof, comprising receiving a bio-signal data, blood test data, and clinical characteristic data for a subject; and predicting appropriateness of antibiotic therapy for the subject based on the received bio-signal data, blood test data, and clinical characteristic data using a prediction model configured to predict the appropriateness of antibiotic use with the bio-signal data, blood test data, and clinical characteristic data as input.

The invention belongs to the technical field of biology, and relates to application of bacteriophage AS25-GD in preparation of drugs for treating or preventing and controlling aquaculture bacterial diseases. The bacteriophage can effectively inhibit the growth of aeromonas salmonicida and crack aeromonas hydrophila, and in addition, the bacteriophage or a method of combining the bacteriophage with antibiotics is used for replacing a pure antibiotic therapy, so that the drug resistance of bacteria to antibiotics can be effectively reduced.

The application discloses a gallium ion and enzyme co-loaded antibacterial agent and a preparation method and application thereof. The antibacterial agent can break through the influence of a microbial cell wall and a biofilm, further release gallium ions to produce active oxygen, metabolic interference and the like, and cooperatively kill or inhibit microorganisms. The antibacterial agent is different from existing antibiotic therapy, and the problem of microbial drug resistance is weakened. Meanwhile, the gallium ions, enzymes and nano carriers used have obvious safety advantages relative to commonly used metal silver ions and the like antibacterial ions. The antibacterial agent can be further applied to antibacterial treatment of infectious diseases such as a microbial infected skin wound and a microbial infected eye wound, and has excellent treatment effect.